Showing results (181-190 of 214) with videos related to

Sort By:
Pageof 22
Autophagy|August 29, 2018
Transcriptional and epigenetic profiling of nutrient-deprived cells to identify novel regulators of autophagyJ G C Peeters, L W Picavet, S G J M Coenen, et al.
Atherosclerosis|September 3, 2020
Complementary roles of platelet αIIbβ3 integrin, phosphatidylserine exposure and cytoskeletal rearrangement in the release of extracellular vesiclesAlexandra C A Heinzmann, Mieke F A Karel, Daniëlle M Coenen, et al.
Cells|August 27, 2021
Inhibition of Phosphodiesterase 3A by Cilostazol Dampens Proinflammatory Platelet FunctionsDaniëlle M Coenen, Alexandra C A Heinzmann, Silvia Oggero, et al.
Blood Advances|June 5, 2025
Uncovering the role of the Hsp40 family member cysteine string protein-α in mouse plateletsAlexis N Smith, Hammodah R Alfar, Smita Joshi, et al.
European Journal of Cancer (Oxford, England : 1990)|December 22, 2017
A randomised phase II trial of docetaxel versus docetaxel plus carboplatin in patients with castration-resistant prostate cancer who have progressed after response to prior docetaxel chemotherapy: The RECARDO trialEsther W Bouman-Wammes, H Pieter van den Berg, Linda de Munck, et al.
European Journal of Cancer (Oxford, England : 1990)|June 9, 2012
Randomised phase II/III study of docetaxel with or without risedronate in patients with metastatic Castration Resistant Prostate Cancer (CRPC), the Netherlands Prostate Study (NePro)H J Meulenbeld, E D van Werkhoven, J L L M Coenen, et al.
ESC Heart Failure|July 11, 2025
Immuno-haemostatic dysregulation in heart failure with preserved ejection fractionGiorgia D'Italia, Daniëlle M Coenen, Titus P Lemmens, et al.
The Lancet. Haematology|June 12, 2022
Short versus extended treatment with a carbapenem in patients with high-risk fever of unknown origin during neutropenia: a non-inferiority, open-label, multicentre, randomised trialNick A de Jonge, Jonne J Sikkens, Sonja Zweegman, et al.
Annals of Surgical Oncology|December 10, 2015
Should ALPPS be Used for Liver Resection in Intermediate-Stage HCC?J G D'Haese, J Neumann, M Weniger, et al.
Frontiers in Pharmacology|February 11, 2026
Designing integrated early-phase protocols to reduce substantial modifications, including considerations for patient cohorts - a multi-stakeholder consensus view for a practical approach in GermanyR Schultz-Heienbrok, S Baumann, R Böhm, et al.
Pageof 22